Association of Periodontal Status and Smoking With Salivary Inflammasome Markers
The Impact of Periodontal Status and Smoking on Salivary Inflammasome Levels: A Cross-Sectional Study
Uskudar University
116 participants
Dec 23, 2025
OBSERVATIONAL
Conditions
Summary
The aim of this study is to evaluate the relationship between periodontal status and salivary levels of the inflammasomes NOD-like receptor family, pyrin domain containing 3 (NLRP-3), NOD-like receptor family, pyrin domain containing 6 (NLRP-6), NOD-like receptor family, pyrin domain containing 12 (NLRP-12), NOD-like receptor family, CARD domain containing 5 (NLRC-5), interleukin-1 beta (IL-1β) and interleukin-10 (IL-10). Furthermore, this study aims to investigate whether the salivary levels of these inflammasomes may serve as potential diagnostic biomarkers for distinguishing individuals with periodontitis from those without. In addition, the potential role of smoking in modulating the relationship between periodontal status and salivary inflammasome levels will also be explored.
Eligibility
Inclusion Criteria3
- systemically healthy,
- clinical diagnosis of periodontitis,
- clinical diagnosis of periodontal health
Exclusion Criteria6
- history of regular use of systemic antibiotics, anti-inflammatory, or antioxidant drugs (previous 6 months);
- nonsurgical periodontal treatment (previous 6 months);
- surgical periodontal treatment (previous 12 months);
- presence of \<20 teeth;
- current medications affecting gingival health (calcium channel blockers, phenytoin, cyclosporine, and hormone replacement therapy);
- diabetes diagnosis; rheumatoid arthritis diagnosis; and pregnancy, lactating, or excessive alcohol consumption.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
With periodontal evaluation, plaque percentage, probing pocket depth, percentage of bleeding on probing, clinical attachment level, number of teeth, periodontal inflammatory surface area (PISA) parameters are recorded.
Levels of salivary NOD-like receptor family, pyrin domain containing 3 (NLRP-3), NOD-like receptor family, pyrin domain containing 6 (NLRP-6), NOD-like receptor family, pyrin domain containing 12 (NLRP-12), NOD-like receptor family, CARD domain containing 5 (NLRC-5), interleukin-1 beta (IL-1β), and interleukin-10 (IL-10) will be determined using an enzyme-linked immunosorbent assay (ELISA).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07312552